State & Federal Policy
The rising costs of prescription drugs and events such as the Vioxx disaster have incresed public scrutiny of the nexus between pharmaceutical marketing and medicine. In some states disclosure laws have been enacted, requiring the pharmaceutical and medical device intustries to report their financial relationships with prescribers. A federal bill to this effect has also been introduced in Congress.
Other legislative efforts have been focused on the creation of alternate prescriber education progams, or "academic detailing", to counterbalance the information provided to doctors by industry sales representatives. The pages under this section contain an overview of current federal, state and organization initiatives to examine and regulate pharmaceutical marketing and promte appropriate prescribing.
For further information on legislative activity and action, please use the links below: